MedTrace Logo

MK0457 in Patients With Leukemia (0457-003)

NCT00111683 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2015-08-25

No results posted yet for this study

Summary

In this study participants with relapsed/refractory leukemia will be given MK-0457 in sequential cohorts and with varying treatment duration to determine the maximum tolerated dose (MTD) for MK-0457.

Conditions

  • Chronic Myelogenous Leukemia in Blast Crisis
  • Lymphocytic Leukemia, B Cell, Acute
  • Myelodysplastic Syndromes
  • Myelogenous Leukemia, Chronic

Interventions

DRUG

MK0457

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2008-05-31
Completion
2008-05-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00111683 on ClinicalTrials.gov